A#2582 McInnes Sonelokimab - IL17A,F nanobody Prior P2 in PsO, HS ARGO: P2 W24 RCT Significant improv in ACR response High PASI90/100 data Up to 60% achieved MDA by W24 Improved PsAID domains (PRO) Safety no IBD, MACE, depr. 2% oral candida IZAR-1,2 - P3 ongoing #ACR24 @RheumNow https://t.co/O4fEhTC8jK